 |
|
Evaluation of UML-491 in the Treatment of Vascular HeadachesAn Analysis of the Effects of 1-Methyl-D-Lysergic Acid (+) Butanolamide Bimaleate (Methysergide)
ARNOLD P. FRIEDMAN, M.D.;
SHELDON LOSIN, M.D.
Arch Neurol. 1961;4(3):241-245.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Introduction
The chemotherapeutic prevention and treatment of vascular headache of the migraine type has been a troublesome problem. Indicative of the lack of really successful treatment is the fact that approximately 400 ways of "curing" vascular headaches have been reported in the literature. A previous pilot study of a serotonin antagonist, 1-methyl-D-lysergic acid (+) butanolamide bimaleate, was made by one of the authors, and it suggested that in many instances this compound was an effective agent in the management of migraine headache.1 Similar conclusions were drawn by Sicuteri and published previously.2 Further appraisal of this drug was indicated. The following is a report of a continuing study of this compound conducted at the Montefiore Hospital Headache Unit over the past 12 months.
In discussing any new drug, it is well to point out pertinent points in its chemistry and pharmacology.
One-Methyl-D-lysergic acid (+ ) butanolamide bimaleate (methysergide) (UML-491) is related to
. . . [Full Text PDF of this Article]
Author Affiliations
NEW YORK
Montefiore Hospital Headache Unit, Division of Neurology and Columbia University College of Physicians and Surgeons, Department of Neurology.
Footnotes
Received for publication Dec. 1, 1960.
Originally presented at AMA in June, 1960, and rewritten for publication.
Methysergide (UML-491) was supplied by Sandoz Pharmaceutical Company as Sansert.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
